SureTrader
Interactive Brokers Advertisement
Home > Boards > US Listed > Medical - Drugs >

Apricus Biosciences, Inc. (APRI)

APRI RSS Feed
Add APRI Price Alert      Hide Sticky   Hide Intro
Moderator: ash111
Search This Board: 
Last Post: 12/12/2017 3:10:21 PM - Followers: 191 - Board type: Free - Posts Today: 0

Apricus Biosciences, Inc. (APRI) 

 

 

http://www.apricusbio.com/

 

 

 

 

Company Address:

11975 El Camino Real, Suite 300
San Diego, CA 92130
T (858) 222-8041

 CIK:   0001017491

Apricus Website:    http://www.apricusbio.com/index.html

 

 
 

NexACT® - Multi-Route Drug Delivery Technology

NexACT® Multi-Route drug delivery technology facilitates compounds crossing the lipid bilayer and yet biodegrades in vivo to natural amino acids and natural fatty acids.

This technology is useful for:
  • Penetrating, proprietary, topical & transdermal formulations.
    Improving oral bioavailability of poorly soluble, poorly permeating compounds (BCS class 2-4)
    Delivering siRNA therapeutics into the cells; in vivo validated
    Development of more effective, penetrating cosmeceutic formulations
    Preservative

The safety and permeation properties of this proprietary drug delivery technology was demonstrated in the Vitaros® product which was approved for the treatment of erectile dysfunction in November 2010 by Health Canada, and approved by the European Union in June 2013.  Vitaros has been launched in all European Union countries by partner pharmaceutical companies.  Additional agreements for marketing Vitaros have been established.  For more information see the company's most recent 10K SEC filing.

In September 2015 the company anounced an agreement with Allergan to reacquire marketing rights for Vitaros in the U.S.  The company expects to resubmit a filing for FDA approval of Vitaros in the second half of 2016.  For more information see the company's most recent 10K SEC filing.


The company expects to initiate a Phase IIb clinical trial for RayVa to treat Reynaud's Syndrome in the second half of 2016.

In October 2014, the company acquired U.S. development and licensing rights to Fispemifene, a Selective Estrogen-Receptor Modulator (SERM) for treatment of secondary hypogonadism.  In March 2016 the company discontinued development Fispemifene after disappointing Phase IIb results.
.

 Filings:  http://www.sec.gov/cgi-bin/browse-edgar?company=&match=&CIK=0001017491&filenum=&State=&Country=&SIC=&owner=exclude&Find=Find+Companies&action=getcompany

Share Structure:
Outstanding Shares
 61,78M

Authorized Shares
75,000,000
  

Investor Relations:
ir@apricusbio.com
Tel: +1-858 222-8041

Matthew Beck
The Trout Group
:(646)378 2933

 

 

 

All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.

 

Please keep your posts on topic because your message(s) will probably be deleted when:
* Posting content that's off-topic to the subject of this board;
* Posting statements that don't add value to the discussion; or
* When you violate any other posting term of the iHub User Agreement: http://investorshub.advfn.com/boards/complex_terms.asp

 


                                                                           
Image result for vitaros                                                  

Image result for vitaros

SureTrader
Interactive Brokers Advertisement
APRI
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
APRI News: Notice of Effectiveness (effect) 12/08/2017 06:01:32 AM
APRI News: Securities Registration Statement (simplified Form) (s-3/a) 12/01/2017 04:17:10 PM
APRI News: Current Report Filing (8-k) 11/02/2017 04:12:25 PM
APRI News: Quarterly Report (10-q) 11/02/2017 04:11:42 PM
APRI News: Securities Registration Statement (simplified Form) (s-3) 11/02/2017 04:10:11 PM
PostSubject
#27427  Sticky Note Apricus approval could lead to Allergan takeover, says ash111 11/06/17 02:32:56 PM
#27441   makes sense, the most recent plan by RPRX eicoman 12/12/17 03:10:21 PM
#27440   I read article about it, gave the impression PuuliTuku 12/12/17 01:43:30 PM
#27439   Repros just got bought out by Allergan, why eicoman 12/12/17 08:21:16 AM
#27438   Hey Aprilov, when is the Christmas Party at casinokid11211 12/10/17 07:34:34 AM
#27437   Ok that is the date I had in dmsrz8 12/08/17 09:32:16 AM
#27436   PDUFA date for NDA resubmission February 17, 2018 ash111 12/08/17 09:31:08 AM
#27435   When if the date again? I have seen dmsrz8 12/08/17 09:29:43 AM
#27434   Agree. a strong hold towards PDUFA date. this ash111 12/05/17 03:19:19 PM
#27433   If it stays green today we have a bigblue72 12/05/17 11:36:49 AM
#27431   Apricus Biosciences, Inc (NASDAQ:APRI) Rating Reiterated by HC ash111 11/15/17 01:46:39 AM
#27430   thanks for sharing. I have a large position ash111 11/13/17 04:21:49 PM
#27429   I picked up 5k today. Like the looks Nedly0 11/13/17 04:19:28 PM
#27428   somebody grabbed a sizable position earlier today, it ash111 11/07/17 03:04:28 PM
#27427   Apricus approval could lead to Allergan takeover, says ash111 11/06/17 02:32:56 PM
#27426   Yes, often a rights offering is used as nsomniyak 11/06/17 11:33:46 AM
#27425   thanks ns, is that the thing they call eicoman 11/06/17 11:31:54 AM
#27424   Increases the odd that $APRI Vitaros gets an ash111 11/06/17 10:58:44 AM
#27423   A shelf does not prevent a takeover. A nsomniyak 11/06/17 10:21:51 AM
#27422   I agree ns, also does it prevent take eicoman 11/06/17 10:14:59 AM
#27421   Vitaros will be approved !!! With DDAIP will Aprilov 11/06/17 07:34:52 AM
#27420   Hey Aprilov,chime in on this casinokid11211 11/05/17 05:53:28 PM
#27419   Having a shelf out there allows a company nsomniyak 11/05/17 02:55:05 PM
#27418   According to the Apricus website institutional, mutual funds, mean gene 11/05/17 02:13:43 PM
#27417   Any thoughts on why a mixed shelf was mean gene 11/05/17 02:07:30 PM
#27416   Richard Pascoe mecosmo2 11/05/17 09:18:50 AM
#27414   APRI Analysts at H.C. Wainwright Maintained their “Buy” ash111 11/03/17 10:59:08 AM
#27413   liking: As of September 30, 2017 , the ash111 11/02/17 04:35:16 PM
#27412   hird Quarter and Year-to-Date Financial Results mecosmo2 11/02/17 04:33:46 PM
#27411   $APRI marketing approval FDA PDUFA date Feb. 2018, ash111 11/02/17 05:46:01 AM
#27410   here's some good info from the link: A eicoman 11/01/17 10:02:45 AM
#27409   Apri. Lifted to buy at Zacks!! mecosmo2 11/01/17 08:55:59 AM
#27408   APRI interesting Coverage https://www.americanbankingnews.com/2017/10/31/apricus ash111 11/01/17 05:26:20 AM
#27407   tic tock,per last SEC filing, institutions ownership has ash111 10/26/17 01:32:15 PM
#27406   AN DIEGO, Oct. 26, 2017 (GLOBE NEWSWIRE) -- mecosmo2 10/26/17 09:01:46 AM
#27405   $APRI P/E 3.06 Bunti 10/20/17 09:39:13 AM
#27404   $APRI charts looks good Bunti 10/20/17 08:56:34 AM
#27403   https://static2.seekingalpha.com/uploads/sa_presentations/354/15354/slides/4.jpg?1508350673 mecosmo2 10/18/17 03:24:06 PM
#27402   Apricus Biosciences to Present at the 2017 BIO mecosmo2 10/10/17 07:44:00 AM
#27401   3 million shares coming onto the market at IPO$ 10/03/17 11:52:55 AM
#27400   Title of Class of Securities to be Registered IPO$ 10/03/17 11:52:05 AM
#27399   New Update: Apricus Biosciences, Inc. (NASDAQ CM: APRI) IPO$ 10/03/17 11:50:43 AM
#27398   Pascoe has no intentions of selling. He can casinokid11211 10/01/17 09:05:32 AM
#27396   3 ways to become a Profitable Stock Trader Ronnieg 09/22/17 07:18:03 PM
#27394   ARMISTICE CAPITAL LLC now owns 9.6% of APRI PuuliTuku 09/22/17 06:43:19 AM
#27393   there are many pharmacies right over the border eicoman 09/21/17 03:00:39 PM
#27392   Yes the product is available in Mexico, I mecosmo2 09/21/17 12:15:58 PM
#27391   supposed to be, check with the pharmacies down eicoman 09/20/17 10:21:28 AM
#27390   Hey Eicoman -- is the Mexico launch still Bryce Harper 09/19/17 04:14:07 PM
#27389   There you have it. Did they need the OldtimeramI 09/12/17 11:23:30 AM
#27388   Pascoe wore yours out before he could get casinokid11211 09/12/17 06:08:24 AM
PostSubject